Variables | Adjusted OR | 95% CI | p value |
---|---|---|---|
All cycles | Â | Â | Â |
P(ng/mL) | 0.42 | 0.30–0.60 | < 0.001 |
P/E2 ratio | 0.97 | 0.79–1.20 | 0.774 |
long GnRH agonist | Â | Â | Â |
P(ng/mL) | 0.30 | 0.14–0.61 | 0.001 |
P/E2 ratio | 1.44 | 0.33–6.30 | 0.626 |
ultralong GnRH agonist | Â | Â | Â |
P(ng/mL) | 0.33 | 0.18–0.60 | < 0.001 |
P/E2 ratio | 0.94 | 0.71–1.24 | 0.648 |
GnRH antagonist | Â | Â | Â |
P(ng/mL) | 0.70 | 0.41–1.17 | 0.169 |
P/E2 ratio | 1.14 | 0.66–1.95 | 0.638 |